Brown TM, Vera-Llonch M, Kanu C, Sikora Kessler A, Yarlas A, Fehnel SE. Cross-sectional quantitative evaluation of a novel patient-reported outcome measure in familial chylomicronemia syndrome. Patient Relat Outcome Meas. 2024 Feb 15;15:45-59. doi: 10.2147/PROM.S441583
Khan AH, Kosa K, De Prado Gomez L, Whalley D, Kamat S, Clark M. Content validation of patient-reported sleep measures and development of a conceptual model of sleep disturbance in patients with moderate-to-severe, uncontrolled asthma. Patient Relat Outcome Meas. 2023 Mar 23;14:57-71. doi: 10.2147/PROM.S392666
Coles T, Chen K, Nelson L, Harris N, Vera-Llonch M, Krasner A, Martin S. Psychometric evaluation of the hypoparathyroidism symptom diary. Patient Relat Outcome Meas. 2019 Jan 29;2019(10):25-36. doi: 10.2147/PROM.S179310
Camprodon-Rosanas E, Ribas-Fito N, Batlle-Vila S, Persavento C, Alvarez-Pedrerol M, Sunyer J, Forns J. Sluggish cognitive tempo: sociodemographic, behavioral, and clinical characteristics in a population of Catalan school children. J Atten Disord. 2017 Jun;21(8):632-41. doi: 10.1177/1087054716652477
Camprodon-Rosanas E, Ribas-Fito N, Batlle S, Persavento C, Alvarez-Pedrerol M, Sunyer J, Forns J. Association between sluggish cognitive tempo symptoms and attentional network and working memory in primary schoolchildren. J Atten Disord. 2017 Apr 1. doi: 10.1177/1087054717702245
Vilor-Tejedor N, Alemany S, Forns J, Caceres A, Murcia M, Macia D, Pujol J, Sunyer J, Gonzalez JR. Assessment of susceptibility risk factors for ADHD in imaging genetic studies. J Atten Disord. 2016 Aug 17.
Deal LS, Sleeper-Triplett J, DiBenedetti DB, Nelson L, McLeod L, Haydysch EE, Brown TM. Development and validation of the ADHD Benefits of Coaching Scale (ABCS). J Atten Disord. 2015 Mar;19(3):191-9. doi: 10.1177/1087054714558118
Karve SJ, Panish JM, Dirani RG, Candrilli SD. Health care utilization and costs among Medicaid-enrolled patients with schizophrenia experiencing multiple psychiatric relapses. Health Outcomes Res Med. 2012 Nov 1;3(4):e183-94.
Karve S, Misurski D, Miller J, Davis KL. Costs of sequelae associated with invasive meningococcal disease: findings from a US managed care population. Health Outcomes Res Med. 2011 Nov 1;2(4):e215-26.
Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA. Toward development of a fibromyalgia responder index and disease activity score: oMERACT module update. J Rheumatol. 2011 Jul 1;38(7):1487-95.
Choy EH, Arnold LM, Clauw DJ, Crofford LJ, Glass JM, Simon LS, Martin SA, Strand CV, Williams DA, Mease PJ. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009 Oct 1;36(10):2330-4.
Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, Strand CV, Williams DA. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009 Oct 1;36(10):2318-29.
Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, Sharma U. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008 Mar;35(3):502-14.
Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, Chappell A, Choy E, Clauw D, Dadabhoy D, Gendreau M, Goldenberg D, Littlejohn G, Martin SA. OMERACT 8 workshop: fibromyalgia syndrome. J Rheumatol. 2007 Jun;34(6):1415-25.
Buchner DA, Graboys TB, Johnson K, Mordin MM, Goodman L, Partsch DS, Goss TF. Development and validation of the ITG Health-Related Quality-of- Life Short-Form measure for use in patients with coronary artery disease. Integrated Therapeutics Group. Clin Cardiol. 2001 Aug;24(8):556-63.
Neville C, Whalley D, McKenna SP, Le Comte M, Fortin PR. Adaptation and validation of the Rheumatoid Arthritis Quality of Life Scale for use in Canada. J Rheumatol. 2001 Jul 1;28(7):1505-10.
Perez-Gutthann S, Petri M, Hochberg MC. Comparison of two methods of classifying patients with systemic lupus erythematosus. J Rheumatol. 1991 Aug 1;18(8):1176-9.